Merck can’t prove its Alzheimer’s drug works, yet, but it did just explain why it’s spending a fortune on PhIII
Investigators for Merck $MRK have very carefully outlined all the early-stage human and animal data they can muster for their Alzheimer’s drug verubecestat. Now in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.